Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Net Income (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Net Income for 11 consecutive years, with -$30.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income fell 232.94% year-over-year to -$30.6 million, compared with a TTM value of -$99.9 million through Sep 2025, down 1155.06%, and an annual FY2024 reading of -$35.1 million, down 11.37% over the prior year.
  • Net Income was -$30.6 million for Q3 2025 at Avalo Therapeutics, down from -$20.8 million in the prior quarter.
  • Across five years, Net Income topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
  • Average Net Income over 4 years is -$8.7 million, with a median of -$8.2 million recorded in 2023.
  • Peak annual rise in Net Income hit 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
  • Year by year, Net Income stood at -$66000.0 in 2021, then tumbled by 12275.76% to -$8.2 million in 2023, then crashed by 332.65% to -$35.3 million in 2024, then increased by 13.34% to -$30.6 million in 2025.
  • Business Quant data shows Net Income for AVTX at -$30.6 million in Q3 2025, -$20.8 million in Q2 2025, and -$13.1 million in Q1 2025.